Fig. 4
From: HDAC inhibitors modulate Hippo pathway signaling in hormone positive breast cancer
Pan-cancer transcriptomic analysis reveals upregulation of CCDC80 and GADD45A in tumor tissue in breast cancer patient samples. A, B Comparison of tumor and normal samples for CCDC80 expression (A) or GADD45A expression (B), from 31 TCGA datasets, analyzed by GEPIA2 web browser database. Datasets showing decreased CCDC80 expression in tumor versus normal are shown here. C Comparison of Hippo pathway genes between HDAC1 high versus HDAC1 low patient samples analyzed from the METABRIC database. D Comparison of Hippo pathway genes between HDAC2 high versus HDAC2 low patient samples analyzed from the METABRIC database. E Proposed mechanism for this study. In our current working model, HDAC inhibitors result in downregulation of YAP and ESR1 expression transcriptionally, while activating TEAD-based transcriptional activation of Hippo pathway downstream genes including CCDC80 and GADD45A. Higher expression of CCDC080 and GADD45A is associated with improved outcomes in HR( +) HER2(−) breast cancer